Winton Group’s Puma Biotechnology PBYI Stock Holding History

Winton Group’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$329K	Sell	40,509 -25,824	-39%	-$189K	0.01%	859
2026 Q1	$424K	Sell	66,333 -30,826	-32%	-$199K	0.01%	759
2025 Q4	$578K	Buy	97,159 +35,835	+58%	+$190K	0.02%	605
2025 Q3	$326K	Buy	+61,324	New	+$260K	0.01%	619
2025 Q1	–	Sell	-38,241	Closed	-$117K	–	765
2024 Q4	$117K	Sell	38,241 -270,739	-88%	-$788K	0.01%	579
2024 Q3	$788K	Buy	308,980 +8,381	+3%	+$25.4K	0.06%	362
2024 Q2	$980K	Buy	300,599 +112,316	+60%	+$493K	0.07%	253
2024 Q1	$998K	Buy	+188,283	New	+$1.01M	0.07%	261
2020 Q3	–	Sell	-26,053	Closed	-$272K	–	1574
2020 Q2	$272K	Sell	26,053 -6,517	-20%	-$67.4K	0.01%	1303
2020 Q1	$275K	Sell	32,570 -211,468	-87%	-$2.05M	0.01%	1186
2019 Q4	$2.13M	Buy	244,038 +218,689	+863%	+$1.81M	0.03%	772
2019 Q3	$273K	Buy	+25,349	New	+$274K	﹤0.01%	1307

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winton Group's PBYI Position: Q2 2026 in Review

Winton Group reduced its Puma Biotechnology (PBYI) stake by 39% in Q2 2026, selling an estimated $189K and leaving 40,509 shares worth $329K. The position accounts for 0.01% of the portfolio, ranked #859.

Winton Group first reported a position in PBYI in Q3 2019 and has held it in 12 quarters since. The position peaked at $2.13M in Q4 2019. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

Winton Group held 40,509 shares of Puma Biotechnology worth $329K as of Q2 2026.
Winton Group sold 25,824 Puma Biotechnology shares in Q2 2026, an estimated $189K.
Puma Biotechnology made up 0.01% of Winton Group's portfolio in Q2 2026, its #859 holding.
Winton Group first reported a position in Puma Biotechnology in Q3 2019 and has held it in 12 quarters since.
Winton Group's Puma Biotechnology position peaked at $2.13M in Q4 2019.
160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.